The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
Adiposity and Neurological Disorders: A Review
14 Mins
